Aripiprazole is effective for treatment of delayed sleep phase syndrome

Manabu Takaki, Hiroshi Ujike

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.

Original languageEnglish
Pages (from-to)123-124
Number of pages2
JournalClinical Neuropharmacology
Volume37
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Circadian Rhythm Sleep Disorders
Sleep
Sleep Initiation and Maintenance Disorders
Serotonin 5-HT1 Receptor Antagonists
Therapeutics
Receptor, Serotonin, 5-HT2A
Receptor, Serotonin, 5-HT1A
Histamine Release
Antipsychotic Agents
Aripiprazole

Keywords

  • aripiprazole
  • delayed sleep phase syndrome
  • depression
  • histamine
  • insomnia

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Aripiprazole is effective for treatment of delayed sleep phase syndrome. / Takaki, Manabu; Ujike, Hiroshi.

In: Clinical Neuropharmacology, Vol. 37, No. 4, 2014, p. 123-124.

Research output: Contribution to journalArticle

@article{f0ce3bd97c514048b732c524eb9a71b6,
title = "Aripiprazole is effective for treatment of delayed sleep phase syndrome",
abstract = "Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.",
keywords = "aripiprazole, delayed sleep phase syndrome, depression, histamine, insomnia",
author = "Manabu Takaki and Hiroshi Ujike",
year = "2014",
doi = "10.1097/WNF.0000000000000035",
language = "English",
volume = "37",
pages = "123--124",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Aripiprazole is effective for treatment of delayed sleep phase syndrome

AU - Takaki, Manabu

AU - Ujike, Hiroshi

PY - 2014

Y1 - 2014

N2 - Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.

AB - Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.

KW - aripiprazole

KW - delayed sleep phase syndrome

KW - depression

KW - histamine

KW - insomnia

UR - http://www.scopus.com/inward/record.url?scp=84925354208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925354208&partnerID=8YFLogxK

U2 - 10.1097/WNF.0000000000000035

DO - 10.1097/WNF.0000000000000035

M3 - Article

VL - 37

SP - 123

EP - 124

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 4

ER -